Skip to main content

News

Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
12/09/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
11/30/2022
Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting
DownloadPDF format download (opens in new window)
11/18/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
11/17/2022
Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China
DownloadPDF format download (opens in new window)
11/17/2022
Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board
DownloadPDF format download (opens in new window)
11/07/2022
Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering
DownloadPDF format download (opens in new window)
11/07/2022
Marinus Pharmaceuticals Announces Proposed Public Offering
DownloadPDF format download (opens in new window)
11/07/2022
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
DownloadPDF format download (opens in new window)
10/31/2022
Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners
DownloadPDF format download (opens in new window)
10/25/2022
Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022
DownloadPDF format download (opens in new window)
10/14/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
10/11/2022
Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings
DownloadPDF format download (opens in new window)
09/22/2022
Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)
DownloadPDF format download (opens in new window)
09/09/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
09/07/2022
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
DownloadPDF format download (opens in new window)
08/29/2022
Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million
DownloadPDF format download (opens in new window)
08/12/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
08/11/2022
 Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
DownloadPDF format download (opens in new window)
07/28/2022
Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder
DownloadPDF format download (opens in new window)
07/15/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
07/14/2022
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
DownloadPDF format download (opens in new window)
07/13/2022
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022
DownloadPDF format download (opens in new window)
06/08/2022
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
DownloadPDF format download (opens in new window)
06/03/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
05/18/2022
Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
DownloadPDF format download (opens in new window)
05/12/2022
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
DownloadPDF format download (opens in new window)
05/10/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
05/05/2022
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
DownloadPDF format download (opens in new window)
04/20/2022
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
DownloadPDF format download (opens in new window)
04/18/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
04/14/2022
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
DownloadPDF format download (opens in new window)
03/31/2022
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
DownloadPDF format download (opens in new window)
03/21/2022
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
DownloadPDF format download (opens in new window)
03/18/2022
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
DownloadPDF format download (opens in new window)
03/15/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
02/22/2022
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
DownloadPDF format download (opens in new window)
02/16/2022
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
DownloadPDF format download (opens in new window)
02/10/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
02/03/2022
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
DownloadPDF format download (opens in new window)
01/14/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
01/05/2022
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
DownloadPDF format download (opens in new window)